What records are connected here?
- Evidence lanes
- 3
- Source years
- 29
- Drugs@FDA applications
- 38
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved4,5Evidence: Smaller human trialsHormones
Desmopressin is a lab-made analogue of vasopressin, the body’s antidiuretic hormone, and the active ingredient in DDAVP.4,5 The DDAVP label covers central diabetes insipidus and primary bedwetting in children. Two placebo-controlled trials in 340 children and teenagers found fewer wet nights with desmopressin.4 The label warns that desmopressin can cause low blood sodium, which can be fatal if not recognized, and says it must not be used by people with low blood sodium or moderate to severe kidney impairment.4
| What it is | A synthetic analogue of the pituitary hormone arginine vasopressin with stronger antidiuretic and weaker blood-pressure effects, according to the DDAVP label.4 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists DDAVP, NDA 019955, with an original approval date of September 6, 1995. The cited label has no boxed warning.4,5 |
| Human evidence | Two randomized, placebo-controlled trials in 340 children and teenagers with bedwetting, and long-term studies in diabetes insipidus, described in the label.4 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Desmopressin is a synthetic version of arginine vasopressin, the pituitary hormone that helps the kidneys hold on to water, with two chemical changes. The label describes it as 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin.4
In the United States it is the active ingredient of DDAVP, approved under NDA 019955, according to Drugs@FDA.5
Like natural vasopressin, desmopressin acts on the kidneys to reduce urine output and concentrate urine. The label states that its structural changes give it less effect on blood pressure and smooth muscle than vasopressin, relative to its antidiuretic effect.4
The label describes two double-blind, randomized, placebo-controlled trials in 340 patients aged 5 to 17 with primary bedwetting. After two weeks, wet nights fell by 10% with placebo and by 27% to 40% with desmopressin.4
In four long-term studies of DDAVP in 46 patients with diabetes insipidus, followed for 12 to 44 months, the label reports no loss of effect and no rise in blood pressure.4
ClinicalTrials.gov also lists desmopressin trials outside the DDAVP label, such as a completed Phase 3 trial in nocturia (NCT01223937) and Phase 3 trials in low blood sodium (NCT06020495) and bleeding risk with kidney disease and surgery (NCT06337838) listed as recruiting in 2026 records.1,2,3
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists DDAVP, application NDA 019955, with an original approval date of September 6, 1995.5
The DDAVP label cited here (DailyMed SPL version 7, published December 10, 2025) states that it is indicated as antidiuretic replacement therapy in central diabetes insipidus and for primary nocturnal enuresis, and that it is ineffective in nephrogenic diabetes insipidus.4
The label has no boxed warning. It warns that desmopressin may lead to water intoxication and low blood sodium, which can be fatal, and that it is contraindicated in people with low blood sodium or moderate to severe kidney impairment.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Desmopressin is not among them.6,7
How it works in older adults: the label states that its clinical studies did not include enough people aged 65 and over to tell whether they respond differently.4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Desmopressin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Desmopressin are a bounded selection, not every registration or paper about Desmopressin. For the years before Desmopressin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Desmopressin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Desmopressin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as DDAVP for diabetes insipidus and bedwetting. Two randomized, placebo-controlled trials in 340 children and teenagers described in the label found fewer wet nights with desmopressin. The label warns of low blood sodium, which can be fatal.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as DDAVP for diabetes insipidus and bedwetting. Two randomized, placebo-controlled trials in 340 children and teenagers described in the label found fewer wet nights with desmopressin. The label warns of low blood sodium, which can be fatal.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date October 30, 2026
ClinicalTrials.gov record NCT06020495↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06020495↗Source date October 30, 2026Literature metadata · added November 16, 2026
Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis.↗Source date October 29, 2026Literature metadata · added November 16, 2026
Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis.↗Source date October 12, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
24 of 25 selected trial records include at least one phase value; 25 of 25 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00223717 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-10-13, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00230594 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00902265 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was desmopressin.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span February 21, 1978 to October 30, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06020495 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was desmopressin.↗
Literature metadata
PubMed lists PMID 35478451 in Reviews in endocrine & metabolic disorders as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2022-04-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42864513 in Neurocritical care as Journal Article, Review, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35199198 in European journal of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2022-02-23 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40728007 in The Cochrane database of systematic reviews as Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06635629 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was desmopressin.↗
Literature metadata
PubMed lists PMID 40176766 in Haematologica as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-04-03 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06337838 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was desmopressin.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 219981 with status AP dated 2026-02-27, and names desmopressin acetate among the application record's active ingredients.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 219873 with status AP dated 2026-02-25, and names desmopressin acetate among the application record's active ingredients.↗
Literature metadata
PubMed lists PMID 27343233 in Pediatrics as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-06-24 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 29055129 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S., Systematic Review, with publication-date metadata of 2017-10-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026